Oculis Announces Phase 2 ACUITY Trial Results at ECTRIMS
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) proudly declared the upcoming presentation of the positive results from the Phase 2 ACUITY trial examining Privosegtor (OCS-05) in patients with acute optic neuritis. This crucial presentation will take place during the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.
Highlights from the ACUITY Trial Results
During the ECTRIMS Congress, one of the central presentations will be titled "Reduction in Retinal Ganglion Cell Loss and Improved Low Contrast Visual Acuity with Privosegtor in Acute Optic Neuritis: Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial." It will be presented by Dr. Céline Louapre from Pitié-Salpêtrière Hospital.
Dr. Louapre is set to present these compelling findings at a session focused on Late Breaking Abstracts, scheduled for the morning of September 24, 2025, at 08:30 CET.
Significant Comments from Oculis Leadership
Dr. Riad Sherif, the Chief Executive Officer of Oculis, expressed enthusiasm about collaborating with Pitié-Salpêtrière Hospital, emphasizing the significance of this trial for patients suffering from acute optic neuritis. He stated, "Topline results revealed clinically meaningful vision improvements, showcasing advancements in retinal structure preservation alongside a favorable safety profile. These findings propose a wide applicability of Privosegtor across multiple neuro-ophthalmic and neurological disorders. We're excited to engage with the MS community as we progress in our studies."
Insights from Dr. Céline Louapre
Dr. Louapre remarked about the privilege of presenting at ECTRIMS, highlighting the promising neuroprotective effects witnessed in the trial. She noted significant enhancements in low contrast visual acuity, reflecting the potential of Privosegtor to positively impact patients experiencing acute relapses of multiple sclerosis.
Understanding Privosegtor (OCS-05)
Privosegtor is an innovative peptoid small molecule candidate aimed at becoming a leading neuroprotective therapy for optic neuritis and related neuro-ophthalmic conditions. The encouraging results from the Phase 2 ACUITY trial demonstrate Privosegtor's capability for neuroprotection through anatomical preservation of the retina coupled with substantial improvements in visual function in individuals suffering from acute optic neuritis.
Promising Animal Model Results
Early studies involving animal models of neuroinflammation and neurodegeneration have mirrored human results. Animals treated with Privosegtor exhibited remarkable preservation of retinal ganglion cells, as well as enhancements in mobility. Price-sensitive behavior is also notable, as the ongoing research could lead to significant developments within neurology and ophthalmology.
About Acute Optic Neuritis
Acute optic neuritis is an infrequent yet serious condition resulting from inflammation of the optic nerve, often leading to permanent visual loss. This condition predominantly affects adults between 20 and 40 years of age, with a higher prevalence in females. Though remyelination can occur once inflammation subsides, the damage to neurons can be irreversible, underscoring the critical need for effective neuroprotective treatments.
The Need for Neuroprotective Therapies
Currently, there are no approved neuroprotective therapies specifically for acute optic neuritis, making the development of Privosegtor paramount. The ongoing trials and research efforts by Oculis aim to meet this crucial medical need.
Oculis: Innovating Healthcare Solutions
Oculis operates as a distinguished global biopharmaceutical entity dedicated to innovating treatment solutions for ophthalmic and neuro-ophthalmic conditions. Their product pipeline showcases potential breakthrough candidates like OCS-01 and OCS-02, focusing on non-invasive treatments for diabetic macular edema and personalized medicine strategies for dry eye disease, respectively. Headquartered in Switzerland, Oculis is managed by a proficient team and backed by leading healthcare investors.
Frequently Asked Questions
What are the Phase 2 ACUITY trial results about?
They showcase the efficacy of Privosegtor in reducing retinal ganglion cell loss and improving visual function in patients with acute optic neuritis.
What is Privosegtor (OCS-05)?
Privosegtor is a neuroprotective drug candidate currently undergoing trials for treatment in acute optic neuritis and other neuro-ophthalmic diseases.
Who will present the trial results at ECTRIMS?
The results will be presented by Dr. Céline Louapre from Pitié-Salpêtrière Hospital.
What is acute optic neuritis?
It is a condition caused by inflammation of the optic nerve, often presenting as the initial symptom of multiple sclerosis.
Is Privosegtor approved for use?
No, it is still an investigational drug in Phase 2 and not yet approved for commercial distribution in any country.
